ALKS.US Alkermes Plc

Healthcare Biotechnology USA Stocks
47.03 USD
Close of Nov 13, 2026
27.00 55.67
Market cap
USD 7.90B
P/E
-
P/B
4.23x
ROE
-3.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALKS.US undervalued?

Graham number

The Graham number of Alkermes Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alkermes Plc fundamental analysis

No fundamental analysis for Alkermes Plc yet.

Alkermes Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alkermes Plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neu…

Full company profile